Cambridge Financial Group Boosted Amerisourcebergen (ABC) Stake By $31.28 Million; Dermira (DERM) Sentiment Is 1.27

March 21, 2018 - By Lawrence Diaz

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company has market cap of $378.07 million. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It currently has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.

Cambridge Financial Group Inc increased Amerisourcebergen Corporation (ABC) stake by 0.58% reported in 2017Q3 SEC filing. Cambridge Financial Group Inc acquired 378 shares as Amerisourcebergen Corporation (ABC)’s stock declined 1.76%. The Cambridge Financial Group Inc holds 66,064 shares with $5.47 billion value, up from 65,686 last quarter. Amerisourcebergen Corporation now has $19.66 billion valuation. The stock increased 0.35% or $0.31 during the last trading session, reaching $89.5. About 1.71M shares traded. AmerisourceBergen Corporation (NYSE:ABC) has risen 18.80% since March 21, 2017 and is uptrending. It has outperformed by 2.10% the S&P500.

Analysts await Dermira, Inc. (NASDAQ:DERM) to report earnings on May, 14. They expect $-1.28 earnings per share, down 62.03% or $0.49 from last year’s $-0.79 per share. After $-1.34 actual earnings per share reported by Dermira, Inc. for the previous quarter, Wall Street now forecasts -4.48% EPS growth.

Since January 1, 0001, it had 0 insider buys, and 13 selling transactions for $1.39 million activity.

Nea Management Company Llc holds 3.32% of its portfolio in Dermira, Inc. for 3.51 million shares. Venbio Select Advisor Llc owns 1.52 million shares or 3.18% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 1.88% invested in the company for 125,000 shares. The United Kingdom-based Abingworth Llp has invested 1.31% in the stock. Dafna Capital Management Llc, a California-based fund reported 75,500 shares.

The stock increased 4.75% or $0.41 during the last trading session, reaching $9.04. About 1.54M shares traded or 0.13% up from the average. Dermira, Inc. (DERM) has declined 7.44% since March 21, 2017 and is downtrending. It has underperformed by 24.14% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: